ArticleInternational journal of general medicine2025
Quantitative Evaluation of Cardiac Function Improvement by Conventional Cardiology Drug Regimens Combined with Sacubitril/Valsartan Sodium in Heart Failure Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the effect of conventional cardiology drug therapy combined with sacubitril/valsartan sodium on improving cardiac function in patients with heart failure. Methods: A retrospective analysis was conducted on data from heart failure patients diagnosed and treated in our hospital between March 2022 and December 2023. Patients were divided into a control group and an experimental group based on treatment methods. The control group received conventional cardiology drug therapy, while the experimental group received conventional cardiology drug therapy combined with sacubitril/valsartan sodium. Cardiac function indicators and related clinical outcomes were compared between the two groups before and after treatment. Results: The overall clinical efficacy rate in the experimental group was significantly higher than in the control group (P < 0.05). After treatment, the experimental group exhibited higher levels of LVEF, SV, and CO, while LVESD and LVEDD levels were significantly lower compared to the control group (P < 0.05). Levels of NT-proBNP, Hcy, and cTnI in the experimental group were significantly lower than in the control group after treatment (P < 0.05). Additionally, levels of NE, ALD, and AngII in the experimental group were significantly lower than those in the control group post-treatment (P < 0.05). The 6-minute walk test (6 MWT) performance was better in the experimental group, and their MLHFQ (Minnesota Living with Heart Failure Questionnaire) scores were lower than those in the control group (P < 0.05). The incidence of adverse events was similar between the two groups (P > 0.05). Conclusion: Conventional cardiology drug therapy combined with sacubitril/valsartan sodium significantly improves cardiac function in patients with heart failure. It achieves this by modulating neuroendocrine function, counteracting adverse effects, and promoting the reversal of ventricular remodeling. The treatment also demonstrates good safety, effectively enhancing patients' exercise capacity and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.